BD Q2 2024 Earnings Report
Key Takeaways
BD reported Q2 2024 financial results with revenue of $5.0 billion, a 4.6% increase as reported. GAAP EPS grew by 20.9% to $1.85, and adjusted diluted EPS increased by 10.8% to $3.17. The company raised its full-year adjusted EPS guidance and affirmed its organic revenue growth guidance.
Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organic.
Q2 GAAP and adjusted diluted EPS of $1.85 and $3.17 grew 20.9% and 10.8%, respectively.
Year-to-date Cash from Continuing Operations of $1.4 billion and Free Cash Flow of $1.1 billion increased $785 million and over $900 million, respectively.
Company raises full-year adjusted EPS guidance and affirms organic revenue growth guidance
BD
BD
BD Revenue by Segment
BD Revenue by Geographic Location
Forward Guidance
The company provided the following guidance with respect to fiscal 2024. The company affirmed its fiscal 2024 organic revenue growth guidance range and increased its adjusted diluted earnings per share guidance range which reflects an increase of 11 cents at the midpoint.
Positive Outlook
- Total Revenues ~$20.1 to $20.3 billion
- Organic Revenue Growth (FXN) 5.5% to 6.25%
- Impact of Surgical Instrumentation Platform Divestiture (~75) basis points
- Revenue Growth (FXN) 4.75% to 5.5%
- Adjusted Diluted EPS $12.95 to $13.15
Challenges Ahead
- Estimated Foreign Currency Impact to Revenue Growth (~65) basis points
- Adjusted Diluted EPS Growth 6.1% to 7.7%
- Estimated Impact of Surgical Instrumentation Platform Divestiture included in Adjusted Diluted EPS (~75) basis points
- Estimated Foreign Currency Impact included in Adjusted Diluted EPS (~425) basis points
- BD's outlook for fiscal 2024 reflects numerous assumptions about many factors that could affect its business, based on the information management has reviewed as of this date.
Revenue & Expenses
Visualization of income flow from segment revenue to net income